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Joint North South All Ireland Rare Disease Conference 2018: 
Patients as Prime Movers in Rare Disease Research 
 
 
Call for abstracts – Poster competition under the following categories: 
 Clinical / Laboratory investigations for Rare Diseases 
 Epidemiology and Big Data contributing to Rare Disease Research 
 Social Science considerations for Rare Diseases 
 Improving Education for Rare Diseases 
 
 
The Joint North South Rare Disease Conference 2018 will be held on 5th March in Riddel Hall, Queen’s 
University, Belfast.  The conference offers participants the opportunity to be part of a global call on 
policy makers, researchers, companies and healthcare professionals to increasingly and more 
effectively involve patients in rare disease research.  The topic for the meeting is ‘Nothing about us 
without us’ and aims to showcase examples of research; academic, clinical, and social, particularly 
where patients and families were engaged and involved; what difference it made; and what is 
happening now and into the future.   
 
 
Abstracts (maximum 200 words, not including title and authors) should be emailed to 
j.mcmullen@qub.ac.uk, with ‘POSTER COMPETITION’ in the subject line, by Monday 26th February 
2018.  Posters must be A0 size in Portrait format and brought to Riddel Hall by 9.00am on 5 March 
2018 for display.   
 
 
A prize of £50 will be awarded to the winning entries in each category and a certificate given to each 
participant.  CPD accreditation has been granted for this event. 
  
     
 
From strategy to action: coproduction and the patient voice in NI: 
Promotion and support for patient participation leads to effective change 
Christine Collins, AJ McKnight, F McLaughlin, T Boggs, IJ Parsley on behalf of NIRDP; 
F Martin, R Wilson on behalf of Department of Health 
 
 
 
 
  
 
Improving Communication for Individuals with a Rare Condition 
 
Ashleen Crowe, Amy Jayne McKnight and Helen McAneney 
 
Centre for Public Health, Queen’s University of Belfast. 
 
 
A rare disease is defined as occurring in <1 in 2,000 people, but cumulatively rare 
diseases are common with one in 17 people in the UK being affected by a rare 
condition. The problems encountered because of the low number of instances of rare 
diseases are vast and need solutions.  Thus improving communication mechanisms 
both within and around the healthcare system is of vital importance to individuals living 
and working with rare diseases. 
 
Surveys amongst people affected by and working with a rare disease have been, and 
will continue to be, carried out to establish what communication for them is like within 
the healthcare system.  The DELPHI model will then be used to identify the priorities 
for improving communication for people with rare disease in Northern Ireland.   
 
From the survey data there were 60 priorities identified which have been grouped 
under 4 headings: Sources of Information, Medical Care, Rare Disease Community, 
and Public Awareness. 
 
There is a huge amount of progress which needs to be made in order to improve how 
someone with a rare disease receives information, treatment, and ultimately holistic 
care to help them deal with the life-changing event of discovering that they have a rare 
disease.  
 
  
 
 
 
 
Improving communication for young people managing a medical condition: 
Evaluation of ‘My Healthcare Passport’ 
 
Dr Janet Diffin and Dr Peter O’Halloran 
 
The School of Nursing and Midwifery, Queen’s University Belfast 
 
 
Most professionals agree that young people with life-threatening or life-limiting 
conditions, and their families, should be fully involved in making decisions related to 
their care. However, fragmented health and social services can often make 
communication challenging. Young people often have to repeat their story to different 
professionals. The use of a patient-held record (PHR) might help overcome such 
communication difficulties. ‘My Healthcare Passport’ is a PHR for people facing long-
term illness (developed through consultation with 41 stakeholder groups throughout 
Northern Ireland). It helps people to share important information between their 
families, carers, and healthcare professionals. Our research project involves working 
with young people aged 16 – 24 years old with a medical condition to evaluate the 
usefulness of ‘My Healthcare Passport’ (this include certain rare diseases). We will 
ask them to use the healthcare passport for up to nine months and speak with them 
three times to find out how useful it has been for them, and whether any improvements 
are needed. The results will provide valuable insight into how ‘My Healthcare Passport’ 
could be used successfully in the future, and reveal the potential benefits of it to young 
people managing a medical condition, including those with rare diseases.  
 
 
 
  
Opsoclonus Myoclonus Ataxia Syndrome: Review of long term outcomes 
 
Nichola Ejaz 
 
Dancing Eye Syndrome Support Trust 
 
 
Aim: Opsoclonus Myoclonus Ataxia Syndrome (OMAS), also known as Dancing Eye 
Syndrome (DES), is a rare inflammatory neurological condition which is thought to 
be due to an autoimmune process. Onset of OMAS/DES often has paraneoplastic or 
post-infectious origins. However, a percentage of cases are classified as idiopathic. 
The tumour type is commonly a neuroblastoma. Treatment of the neuroblastoma, 
while important in its own right, does not appear to alter the outcome of Opsoclonus 
Myoclonus Ataxia Syndrome. Long term neurological and cognitive sequelae are often 
reported.  
 
Methodology: A review of literature, questionnaires and surveys. 
 
Results: Results demonstrate that a large proportion of childhood onset OMAS/DES 
patients experience ongoing neurological sequelae and an episodic nature of disease 
progression.  
 
Implications: Patients with OMAS/DES have represented reduced connectivity and 
grey matter in fMRI imaging which may be representative of the long term outcome of 
these patients. Hyperkinetic movement disorders, ataxia, learning disability, anxiety, 
obsessive-compulsive disorder and cognitive decline are examples of long term 
sequelae. Patients often report an episodic nature of this syndrome due to certain 
triggers such as infection. The onset of puberty seems to be a critical window, the 
transition through which seems to reflect and also predict whether the disease course 
is monophasic or episodic and progressive in nature.  
 
  
  
The measurement of rare cancers 
 
Anna Gavin, Colin Fox, Ronan Campbell, Sinead Lardner, Eileen Morgan 
 
N. Ireland Cancer Registry, Queens University, Belfast 
 
 
The N. Ireland Cancer Registry founded in 1994 provides information on cancers and 
pre-malignant disease occurring in Northern Ireland for research, education, service 
monitoring and planning. It collects morphology codes using international 
classifications and has data on pathologically rare tumours which arise in non-rare 
anatomical sites. E.g. Anaplastic carcinoma of the thyroid.  
 
The registry provides a secure confidential environment for the storage and analysis 
of the sensitive clinical data having received ISO 27001 accreditation.  It has links with 
the NI biobank facilitating the collection of clinical details on biological samples  
 
From 2011 to 2015, on average, there were 4,557 male and 4,516 female patients 
diagnosed with cancer each year excluding Non-Melanoma Skin Cancer (NMSC). 
There were an additional 2,065 male and 1,576 female patients diagnosed with 
NMSC. Included in this total are many rare cancers usually categorised as ‘other’ 
amounting to approximately 1200 cases per year  
 
Work is ongoing at European and international level to standardise recording and 
categorisation of these rare tumours and to combine datasets from many countries to 
enable epidemiological and scientific study including   Joint Action on Rare cancers 
work package 4 - Improving epidemiological surveillance on rare cancers in Europe. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Genomic and Bioinformatic interrogation of rare diseases: Translating multi-
omic research into clinical progress. 
Katie Kerr, Helen McAneney, AJ McKnight 
Centre for Public Health, Queen’s University Belfast 
 
The paradox of rare diseases is that they are individually rare, yet cumulatively over 
350 million people are affected by rare diseases worldwide. There are approximately 
8000 rare disorders, very often with variable clinical presentations, which makes 
diagnosing rare diseases challenging. Two in five rare disease patients report 
difficulties obtaining diagnosis, with many patients waiting several years between first 
symptoms and diagnosis. Without diagnosis patients report decreased quality of life, 
negative impacts on mental health, poor prognosis and difficulties in accessing an 
effective treatment plan. Therefore recent research has been focused on improving 
diagnosis, including molecular characterisation of a rare disease using multi-omic 
approaches. This evaluates differences at the genomic sequence level, such as whole 
genome sequencing through the 100,000 genomes project, but also examining 
epigenomic changes such as differential methylation. 
This project reviews current research into multi-omics of rare disease and ultimately 
leverages multi-omic analyses to identify diagnostic biomarkers where whole genome 
sequencing has been insufficient to render a diagnosis. These allied approaches to 
improve rare disease diagnosis will benefit people living and working with rare disease 
and provide insight into the biological mechanisms of disease leading to potentially 
novel therapeutics.  
 
 
  
 Support and fun for us designed by us 
Sorcha McPhillips 
Huntington’s Disease Association Northern Ireland 
 
 
 
 
  
 
 
Inaugural rare-case simulation series: Improving rare condition education 
among NI Paediatric trainees 
Peter Mallett1, Ben McNaughten2, Thomas Bourke2, Andrew Thompson2. 
1. Clinical Fellow in Education and Simulation. Royal Belfast Hospital for Sick 
Children (RBHSC) , Belfast Health & Social Care Trust 
2. Department of Paediatric Education & Simulation, Royal Belfast Hospital for 
Sick Children 
 
Aims: The Royal College of Paediatrics and Child Health (RCPCH) provides a 
comprehensive curriculum for paediatric trainees. Achieving exposure to more 
uncommon paediatric conditions in clinical practice is often extremely challenging. We 
sought to address this by offering the regions paediatric trainees an opportunity to 
participate in new inter-professional, high-fidelity, simulated scenarios based on rare 
but important clinical conditions. 
Methods: We surveyed all level three paediatric trainees (ST6-ST8) in our deanery 
enquiring about what conditions they had never experienced in clinical practice.  We 
designed and embedded a new ‘rare- case’ simulation teaching programme into the 
postgraduate education schedule in the deanery’s tertiary paediatric centre. 
Results: Tailored simulation scenarios have been designed and currently run on a 
monthly regular basis through our ‘rare case sunrise simulation sessions’. These 
include acute stroke, SVC obstruction and neonatal hyperammonaemia following 
trainee survey. Feedback demonstrated an improvement in confidence and clinical 
knowledge from the trainees following the sessions. Since inception in 2016, over 50 
trainees have benefitted. 
Conclusions: Rare-case simulation allows trainees to develop their confidence in 
managing uncommon conditions and address areas of the college curriculum which 
they have previously struggled to achieve. This has aided rare-disease awareness, 
promotion and improved paediatric trainee education in this area. 
 
 AVERT – Autoimmunity Relapse Prediction using Multiple Parallel Data 
Sources 
Julie Power 
Vasculitis Ireland Awareness 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Just how rare are rare lymphoid malignancies in Europe?  Findings from 
RARECAREnet. 
Charlene M. McShane1 and Lesley A. Anderson1 on behalf of the RARECARE 
working group. 
1Centre for Public Health, Queen’s University Belfast 
 
Background: Rare cancers contribute to 22% of the total cancer burden in Europe 
and are associated with poorer survival when compared to more common cancers.   
Methods: Using data from RARECAREnet, which collates data from 94 European 
population-based registries, we investigated incidence, prevalence and survival of rare 
lymphoid malignancies diagnosed in Europe. 
Results: In 2008, an estimated n=931,855 individuals were living with a rare lymphoid 
malignancy in Europe.  During 2001-2007, n=283,288 new rare lymphoid 
malignancies were diagnosed; age-adjusted incidence rate (ASR): 15.2/100,000 
people.  Higher incidence was observed in males (ASR 18.1 vs 12.8 per 100,000). 
Multiple myeloma/plasmacytoma (and heavy chain disease) and diffuse large B-cell 
lymphoma were the most commonly diagnosed malignancies accounting for 31.6% 
and 23.9% of cases respectively. Across all subtypes, slight increases in 5-year 
relative survival were observed between 1999 and 2007. Survival remains poor for 
prolymphocytic leukaemia B-cell (5-year relative survival: 31%), multiple 
myeloma/plasmacytoma (and heavy chain disease; 35%) and other T-cell lymphomas 
and Natural Killer cell neoplasms (38%).  
Conclusions: Rare lymphoid malignancies are a significant public health problem.  A 
collaborative international approach is required to advance research in this field and 
to ensure patients are afforded the same opportunities as patients diagnosed with 
common cancers. 
 
[Poster withheld] 
 
 
 
 
 
 
 
 
 
 ART and family: Life, but not as you know it 
Susie Rea 
PhD Researcher, Research Institute of Art and Design, Ulster University 
 
Genetics is about people.  Research undertaken by biomedical scientists in support of 
the field touches people.  We are the end users.  However, the human experience of 
the application of these technologies is often side-lined.  The work being produced by 
artists within this interdisciplinary field of study is no exception.  Many practitioners 
have been preoccupied with life at a micro level and the technology that makes this 
molecular view possible.  This trend in ‘reductionism’, though visually fascinating and 
conceptually interesting, has meant that we have lost sight of the “embodied individual” 
(Ayers, 2011) and the human experience.  It is the purpose of this PhD research 
project to address this gap through the creation of a new body of work.  The project 
looks at the experience of families living with genetic disease, with a specific focus on 
the choices they face as a result of developments in the area of advanced reproductive 
technologies (ART).  If art can assist in communicating complex scientific, social and 
ethical ideas visually and experientially to a wider audience, it is the challenge of this 
artist to do so using the humble family photograph.  Susie Rea is a practicing 
photographic artist and PhD researcher at Ulster University.  Her work explores the 
fault lines where medicine, technology and society meet. 
 
 
 
